Lorlatinib is administered orally. Current U.S. LORBRENA labeling recommends 100 mg once daily, with or without food.
The exact instructions for a Lorbrexen product should be checked against its own authorized product information because the commercial product’s formulation and labeling require verification.
General administration principles
- Take lorlatinib exactly as prescribed.
- Follow the prescribed schedule consistently.
- Lorlatinib may be taken with or without food under current U.S. labeling.
- Swallow the dosage form according to the applicable product instructions.
- Do not independently increase, reduce or discontinue treatment.
- Tell the healthcare team about all prescription medicines, nonprescription medicines and supplements.
Missed dose
The current U.S. label provides specific instructions for a missed dose. Patients should consult their prescribing information or healthcare professional rather than taking an additional dose to compensate.
Food
Current U.S. labeling permits LORBRENA to be taken with or without food.
Interactions require particular attention
Strong CYP3A inducers are contraindicated with LORBRENA because of the risk of serious hepatotoxicity. Moderate CYP3A inducers should generally be avoided, and strong CYP3A inhibitors should also be avoided or managed according to the label.
Monitoring
Monitoring may include:
- Lipid levels
- Neurological and cognitive symptoms
- Mood and mental-status changes
- Blood pressure
- Blood glucose
- Cardiac conduction when clinically appropriate
- Pulmonary symptoms
- Liver-function tests when indicated
Storage
Storage requirements for the specific Lorbrexen product are Everest Pharmaceuticals Ltd. Patients should follow the package labeling supplied with their product.